<DOC>
	<DOCNO>NCT00003461</DOCNO>
	<brief_summary>RATIONALE : Radiolabeled monoclonal antibody locate tumor cell deliver radioactive tumor-killing substance without harm normal cell . This may effective treatment primary metastatic brain tumor . PURPOSE : Phase I trial study effectiveness radiolabeled monoclonal antibody therapy treat patient primary metastatic brain tumor .</brief_summary>
	<brief_title>Radiolabeled Monoclonal Antibody Therapy Treating Patients With Primary Metastatic Brain Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxicity monoclonal antibody ( MAb ) Astatine At 211 Antitenascin Human/Mouse Chimeric 81C6 ( At 211 MAb 81C6 ) therapy deliver via intracranial resection cavity patient recurrent primary metastatic malignant brain tumor . - Identify objective therapeutic response patient treatment . OUTLINE : This dose escalation study . Patients undergo surgical resection tumor time indwell intracranial resection cavity catheter surgically place . Patients receive one dose astatine At 211 antitenascin monoclonal antibody 81C6 ( At 211 MAb 81C6 ) via intralesional catheter . Cohorts 3-6 patient treat escalate dos At 211 MAb 81C6 . The maximum tolerate dose high dose 3 6 patient experience dose limit toxicity . Patients follow initially 4 week , approximately 12 week , 24 week , every 12 week 1 year . PROJECTED ACCRUAL : A total 12-24 patient accrue study within 18-24 month .</detailed_description>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm newly diagnose recurrent supratentorial primary metastatic malignant brain tumor Measurable disease MRI CT scan Candidate surgical resection Extension tumor 1.0 cm beyond margin surgical cavity Demonstrated reactivity tumor cell tenascin immunohistology either polyclonal rabbit antibody monoclonal mouse antibody No infratentorial tumor , diffusely infiltrate tumor , tumor subependymal spread , multifocal tumor PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 50100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count great 1000/mm^3 Platelet count great 100,000/mm^3 Hepatic : Bilirubin le 1.5 mg/dL Alkaline phosphatase less 1.5 time normal SGOT le 1.5 time normal Renal : Creatinine le 1.2 mg/dL Other : Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 6 week since prior chemotherapy , unless unequivocal evidence progression Endocrine therapy : Concurrent corticosteroid allow , must stable dose least 1 week Radiotherapy : At least 3 month since prior radiotherapy site measurable disease CNS Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>localize resectable neuroblastoma</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult craniopharyngioma</keyword>
	<keyword>adult medulloblastoma</keyword>
	<keyword>adult meningioma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult oligodendroglioma</keyword>
	<keyword>tumor metastatic brain</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult pineal parenchymal tumor</keyword>
	<keyword>adult central nervous system germ cell tumor</keyword>
	<keyword>adult grade III meningioma</keyword>
	<keyword>adult pilocytic astrocytoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult pineal gland astrocytoma</keyword>
</DOC>